Clever Culture Systems, an Australian-based company focused on environmental monitoring, has reported continued progress for its APAS Independence platform in the first half of fiscal year 2026.
The report highlights the company’s expanding global footprint and strategic focus on major pharmaceutical customers.
What global growth does the report show?
During the period, four new APAS Independence orders were confirmed, bringing the total installed base to 27 units globally, excluding instruments currently leased or under evaluation.
Notable new placements were made with global pharmaceutical manufacturers Novo Nordisk and Boehringer Ingelheim, who are now evaluating the system for broader deployment across their manufacturing networks.
Existing key customers include AstraZeneca, Pfizer, Bristol Myers Squibb, and Thermo Fisher Pharma Services (Patheon).
A significant technological milestone was achieved in August, with the validation of a new analysis module for 55mm contact plates used in pharmaceutical environmental monitoring.
This upgrade, now available to existing customers, positions the APAS Independence as a comprehensive solution for routine environmental monitoring.
Findings about reinforced market presence
The report emphasised ongoing customer support and validation services, which help ensure smooth integration of APAS technology into tightly regulated pharmaceutical processes.
This support not only enhances customer confidence but also contributes to recurring revenue streams through software and service renewals.
Clever Culture Systems also reinforced its market presence through participation in major industry conferences across the US, Europe, Australia, and South Korea.
Presentations by AstraZeneca, Bristol Myers Squibb, and Pfizer showcased positive user experiences, providing third-party validation that underlines the platform’s value and credibility.
Almost all (99.6%) of the company’s CC5OA share options, a type of right allowing holders to buy company shares at a set price, were exercised before they expired in November 2025, raising $3.2m for the company.
A portion of these proceeds was used to repay a $1m government loan, leaving the company debt-free.
What is next?
Looking forward, the company plans to continue its “land and expand” strategy, targeting new placements with major pharmaceutical manufacturers while supporting existing customers during evaluation phases.
Further technology enhancements are expected, including improved plate processing, better integration with customer digital systems, and refined analysis modules based on real-world feedback.
These initiatives aim to expand the APAS Independence installed base, deepen the sales pipeline and drive sustainable growth for shareholders in the coming fiscal years.